Wordt geladen...
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Zanubrutinib is a potent and highly selective inhibitor of Bruton tyrosine kinase (BTK). In this first-in-human, open-label, multicenter, phase 1 study, patients in part 1 (3 + 3 dose escalation) had relapsed/refractory B-cell malignancies and received zanubrutinib 40, 80, 160, or 320 mg once daily...
Bewaard in:
| Gepubliceerd in: | Blood |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Society of Hematology
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6742923/ https://ncbi.nlm.nih.gov/pubmed/31340982 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019001160 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|